Filling the need for trusted information on health issues…

Trending on kff Enrollment Marketplaces Medicare Advantage

Private Sector Involvement

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Political Commitment, Global Support Can Bring NTD Treatments To Those In Need

In a post in the Bill & Melinda Gates Foundation’s “Impatient Optimists” blog, Richard Hatzfeld, communications director at the Sabin Vaccine Institute, discusses a Kenyan family affected by neglected tropical diseases (NTDs) and “captured in a short video from END7, a campaign of the Global Network for Neglected Tropical Diseases.”…

Public, Private Firms Investing In African Health, Manufacturing, R&D

Media sources discuss recent efforts by public and private entities to invest in African health, manufacturing, and research and development. Financial Times: Drugmakers learn to blend commerce with philanthropy in Africa “Africa has rarely been a source of good publicity for big pharma. But two events this week suggest the…

GSK To Add Antiretroviral Drug To Medicines Patent Pool

Reuters: GSK’s ViiV unit adds new HIV drug to AIDS patent pool “GlaxoSmithKline’s AIDS drugs business is to add one of its latest HIV medicines to a patent pool — cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the…

Responsible Business Practices Enable Commercial Successes

The Telegraph: Business has the power to do immense good Andrew Witty, CEO of GlaxoSmithKline “For business, behaving responsibly doesn’t compromise commercial success, it enables it. … Collectively, the private sector has the power to do immense good, using its innovation, resources and reach to create prosperity, provide employment and…

Public Private Partnerships Can Help Create AIDS-Free Generation

Huffington Post: An AIDS-Free Generation Rhonda Zygocki, executive vice president of policy and planning at Chevron Corporation “…[E]nding HIV transmission from mother to child remains one of the most achievable ways to realize an AIDS-free generation — with the potential to bring about an end to new infections, keep mothers…

Deutsche Welle Discusses Balance Between For-Profit Drug Companies And Public Health Needs

Zulfikar Abbany of Deutsche Welle interviews Adrian Hill of the Jenner Institute on the issues and challenges involved in balancing the needs of for-profit pharmaceutical companies with public health goals. Deutsche Welle: Is profit more important than public health? In this audio episode of Spectrum, Zulfikar Abbany of Deutsche Welle…

‘Development Impact Bonds’ Can Drive Malaria Control Programs Forward

The Guardian: Malaria in Mozambique: trialing payment by results Lily Han, investment principal with Dalberg Global Development Advisers, a private sector partner working to launch the Mozambique Malaria performance bond “Malaria control programs in recent decades offer overwhelming evidence that integrated, sustained malaria-eradication protocols that cover prevention, diagnosis, and treatment…

Drugmaker GlaxoSmithKline To Invest $216M In Factories, R&D In Africa

Reuters: Drugmaker GSK to invest $200 million in African factories, R&D “Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as chronic diseases become more common among the continent’s swelling urban middle classes…” (Hirschler, 3/31).

Myanmar Remains Potential ‘Gateway’ for Spread Of Drug-Resistant Malaria, Experts Warn

IRIN: Curbing Myanmar’s spread of drug-resistant malaria “Efforts to halt the spread of drug-resistant malaria in Myanmar have delivered encouraging results through the private health sector, but health experts warn the [fight against the] disease cannot be won outside the public health system — and that the country is still…

Sanofi Expects Dengue Vaccine Clinical Trial Results In September

Reuters: Sanofi faces make-or-break verdict on big dengue vaccine bet “Sanofi expects final clinical results for its vaccine against dengue by late September, the French drugmaker’s project leader has told Reuters, and has already gambled on starting production despite some disappointing early trials data. Sanofi has invested more than one…